United Kingdom

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

16 Feb 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is... (more)


Beta: 0.26
Market Cap(Mil.): $2,541.79
Shares Outstanding(Mil.): 68.44
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 148.59 16.60
EPS (TTM): -- -- --
ROI: -- 9.38 10.66
ROE: -- 14.72 14.30

BRIEF-Myriad Genetics Q2 Adjusted Earnings Per Share $0.31


06 Feb 2018

UPDATE 1-U.S. FDA approves expanded use of AstraZeneca cancer drug

Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

12 Jan 2018

BRIEF-Myriad Genetics posts Q1 adjusted earnings per share $0.26

* Myriad Genetics reports fiscal first-quarter 2018 financial results

07 Nov 2017

BRIEF-Myriad announces GeneSight Psychotropic results from a large prospective trial in patients with major depressive disorder

* Myriad announces GeneSight® Psychotropic results from a large prospective trial in patients with major depressive disorder

02 Nov 2017

BRIEF-‍Myriad Genetics announces new positive results for EndoPredict

* Endopredict (epclin) shown in second study to be more effective than oncotype dx® (rs) in women with intermediate risk of breast cancer recurrence

26 Oct 2017

BRIEF-Myriad submits BRACAnalysis® CDx application for regulatory approval in Japan

* Myriad submits BRACAnalysis® CDX application for regulatory approval in Japan for HER2- metastatic breast cancer

24 Oct 2017

BRIEF-Myriad Genetics’s supplementary PMA for BRACAnalysis CDx accepted by FDA for review

* Myriad’s BRACAnalysis CDx supplementary pma accepted by fda for review as a companion diagnostic for Lynparza (olaparib) in metastatic breast cancer

18 Oct 2017

BRIEF-Myriad Genetics Inc announces launch of riskScore

* Myriad Genetics Inc - September 5, co announced it has launched riskScore - SEC filing Source text: (http://bit.ly/2eDj2Kj) Further company coverage:

05 Sep 2017

Earnings vs. Estimates